{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T02:17:14Z","timestamp":1784945834943,"version":"3.55.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2019,7,15]],"date-time":"2019-07-15T00:00:00Z","timestamp":1563148800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,7,15]],"date-time":"2019-07-15T00:00:00Z","timestamp":1563148800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100000241","name":"Physicians' Services Incorporated Foundation","doi-asserted-by":"publisher","award":["PSI 2015-16"],"award-info":[{"award-number":["PSI 2015-16"]}],"id":[{"id":"10.13039\/501100000241","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs Aging"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1007\/s40266-019-00690-9","type":"journal-article","created":{"date-parts":[[2019,7,15]],"date-time":"2019-07-15T04:02:42Z","timestamp":1563163362000},"page":"875-884","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Sex Differences in the Prevalent Use of Oral Formulations of Cholinesterase Inhibitors in Older Adults with Dementia"],"prefix":"10.1007","volume":"36","author":[{"given":"Lynn","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula A.","family":"Rochon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Gruneir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasily","family":"Giannakeas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter C.","family":"Austin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan M.","family":"Stall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"McCarthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Alberga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Herrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudeep S.","family":"Gill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7341-0655","authenticated-orcid":false,"given":"Susan E.","family":"Bronskill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,7,15]]},"reference":[{"issue":"7512","key":"690_CR1","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1136\/bmj.331.7512.321","volume":"331","author":"H Kaduszkiewicz","year":"2005","unstructured":"Kaduszkiewicz H, Zimmermann T, Beck-Bornholdt HP, van den Bussche H. Cholinesterase inhibitors for patients with Alzheimer\u2019s disease: systematic review of randomised clinical trials. BMJ. 2005;331(7512):321\u20137. \n                    https:\/\/doi.org\/10.1136\/bmj.331.7512.321\n                    \n                  .","journal-title":"BMJ."},{"issue":"2","key":"690_CR2","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.jalz.2010.03.016","volume":"7","author":"G Small","year":"2011","unstructured":"Small G, Bullock R. Defining optimal treatment with cholinesterase inhibitors in Alzheimer\u2019s disease. Alzheimers Dement. 2011;7(2):177\u201384. \n                    https:\/\/doi.org\/10.1016\/j.jalz.2010.03.016\n                    \n                  .","journal-title":"Alzheimers Dement."},{"issue":"8","key":"690_CR3","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1111\/jgs.14226","volume":"64","author":"D Koller","year":"2016","unstructured":"Koller D, Hua T, Bynum JP. Treatment patterns with antidementia drugs in the United States: medicare cohort study. J Am Geriatr Soc. 2016;64(8):1540\u20138. \n                    https:\/\/doi.org\/10.1111\/jgs.14226\n                    \n                  .","journal-title":"J Am Geriatr Soc."},{"issue":"1","key":"690_CR4","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1093\/ageing\/afu143","volume":"44","author":"J Ngo","year":"2015","unstructured":"Ngo J, Holroyd-Leduc JM. Systematic review of recent dementia practice guidelines. Age Ageing. 2015;44(1):25\u201333. \n                    https:\/\/doi.org\/10.1093\/ageing\/afu143\n                    \n                  .","journal-title":"Age Ageing."},{"issue":"12","key":"690_CR5","doi-asserted-by":"publisher","first-page":"e0144337","DOI":"10.1371\/journal.pone.0144337","volume":"10","author":"TB Ali","year":"2015","unstructured":"Ali TB, Schleret TR, Reilly BM, Chen WY, Abagyan R. Adverse effects of cholinesterase inhibitors in dementia, according to the pharmacovigilance databases of the United-States and Canada. PLoS One. 2015;10(12):e0144337. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0144337\n                    \n                  .","journal-title":"PLoS One."},{"key":"690_CR6","doi-asserted-by":"publisher","first-page":"CD005593","DOI":"10.1002\/14651858.cd005593","volume":"1","author":"J Birks","year":"2006","unstructured":"Birks J. Cholinesterase inhibitors for Alzheimer\u2019s disease. Cochrane Database Syst Rev. 2006;1:CD005593. \n                    https:\/\/doi.org\/10.1002\/14651858.cd005593\n                    \n                  .","journal-title":"Cochrane Database Syst Rev."},{"issue":"9","key":"690_CR7","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/S1474-4422(07)70195-3","volume":"6","author":"H Kavirajan","year":"2007","unstructured":"Kavirajan H, Schneider LS. Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials. Lancet Neurol. 2007;6(9):782\u201392. \n                    https:\/\/doi.org\/10.1016\/S1474-4422(07)70195-3\n                    \n                  .","journal-title":"Lancet Neurol."},{"issue":"9","key":"690_CR8","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1111\/jgs.15442","volume":"66","author":"PA Rochon","year":"2018","unstructured":"Rochon PA, Gruneir A, Gill SS, Wu W, Zhu L, Herrmann N, et al. Initial cholinesterase inhibitor therapy dose and serious events in older women and men. J Am Geriatr Soc. 2018;66(9):1692\u20139. \n                    https:\/\/doi.org\/10.1111\/jgs.15442\n                    \n                  .","journal-title":"J Am Geriatr Soc."},{"issue":"10","key":"690_CR9","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1111\/j.1532-5415.2007.01387.x","volume":"55","author":"AL Gruber-Baldini","year":"2007","unstructured":"Gruber-Baldini AL, Stuart B, Zuckerman IH, Simoni-Wastila L, Miller R. Treatment of dementia in community-dwelling and institutionalized medicare beneficiaries. J Am Geriatr Soc. 2007;55(10):1508\u201316. \n                    https:\/\/doi.org\/10.1111\/j.1532-5415.2007.01387.x\n                    \n                  .","journal-title":"J Am Geriatr Soc."},{"issue":"1","key":"690_CR10","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1093\/ageing\/afw176","volume":"46","author":"F Clague","year":"2017","unstructured":"Clague F, Mercer SW, McLean G, Reynish E, Guthrie B. Comorbidity and polypharmacy in people with dementia: insights from a large, population-based cross-sectional analysis of primary care data. Age Ageing. 2017;46(1):33\u20139. \n                    https:\/\/doi.org\/10.1093\/ageing\/afw176\n                    \n                  .","journal-title":"Age Ageing."},{"issue":"3","key":"690_CR11","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1111\/jgs.14034","volume":"64","author":"CE Reppas-Rindlisbacher","year":"2016","unstructured":"Reppas-Rindlisbacher CE, Fischer HD, Fung K, Gill SS, Seitz D, Tannenbaum C, et al. Anticholinergic drug burden in persons with dementia taking a cholinesterase inhibitor: the effect of multiple physicians. J Am Geriatr Soc. 2016;64(3):492\u2013500. \n                    https:\/\/doi.org\/10.1111\/jgs.14034\n                    \n                  .","journal-title":"J Am Geriatr Soc."},{"issue":"4","key":"690_CR12","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.jalz.2006.08.003","volume":"2","author":"ED Huey","year":"2006","unstructured":"Huey ED, Taylor JL, Luu P, Oehlert J, Tinklenberg JR. Factors associated with use of medications with potential to impair cognition or cholinesterase inhibitors among Alzheimer\u2019s disease patients. Alzheimers Dement. 2006;2(4):314\u201321. \n                    https:\/\/doi.org\/10.1016\/j.jalz.2006.08.003\n                    \n                  .","journal-title":"Alzheimers Dement."},{"issue":"11","key":"690_CR13","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1111\/jgs.13702","volume":"63","author":"American Geriatrics Society Beers Criteria Update Expert Panel","year":"2015","unstructured":"American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2015 updated beers criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2015;63(11):2227\u201346. \n                    https:\/\/doi.org\/10.1111\/jgs.13702\n                    \n                  .","journal-title":"J Am Geriatr Soc."},{"issue":"6","key":"690_CR14","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/nrneurol.2017.63","volume":"13","author":"YT Wu","year":"2017","unstructured":"Wu YT, Beiser AS, Breteler MMB, Fratiglioni L, Helmer C, Hendrie HC, et al. The changing prevalence and incidence of dementia over time: current evidence. Nat Rev Neurol. 2017;13(6):327\u201339. \n                    https:\/\/doi.org\/10.1038\/nrneurol.2017.63\n                    \n                  .","journal-title":"Nat Rev Neurol."},{"issue":"5","key":"690_CR15","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/S1474-4422(16)00067-3","volume":"15","author":"CM Mazure","year":"2016","unstructured":"Mazure CM, Swendsen J. Sex differences in Alzheimer\u2019s disease and other dementias. Lancet Neurol. 2016;15(5):451\u20132. \n                    https:\/\/doi.org\/10.1016\/S1474-4422(16)00067-3\n                    \n                  .","journal-title":"Lancet Neurol."},{"key":"690_CR16","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1186\/s12913-016-1435-1","volume":"16","author":"H Tam-Tham","year":"2016","unstructured":"Tam-Tham H, Nettel-Aguirre A, Silvius J, Dalziel W, Garcia L, Molnar F, et al. Provision of dementia-related services in Canada: a comparative study. BMC Health Serv Res. 2016;16:184. \n                    https:\/\/doi.org\/10.1186\/s12913-016-1435-1\n                    \n                  .","journal-title":"BMC Health Serv Res."},{"key":"690_CR17","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.phrs.2016.11.035","volume":"115","author":"M Canevelli","year":"2017","unstructured":"Canevelli M, Quarata F, Remiddi F, Lucchini F, Lacorte E, Vanacore N, et al. Sex and gender differences in the treatment of Alzheimer\u2019s disease: a systematic review of randomized controlled trials. Pharmacol Res. 2017;115:218\u201323. \n                    https:\/\/doi.org\/10.1016\/j.phrs.2016.11.035\n                    \n                  .","journal-title":"Pharmacol Res."},{"issue":"10","key":"690_CR18","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1111\/jgs.15020","volume":"65","author":"N Mehta","year":"2017","unstructured":"Mehta N, Rodrigues C, Lamba M, Wu W, Bronskill SE, Herrmann N, et al. Systematic review of sex-specific reporting of data: cholinesterase inhibitor example. J Am Geriatr Soc. 2017;65(10):2213\u20139. \n                    https:\/\/doi.org\/10.1111\/jgs.15020\n                    \n                  .","journal-title":"J Am Geriatr Soc."},{"issue":"18","key":"690_CR19","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1001\/jama.2016.13995","volume":"316","author":"MJ Legato","year":"2016","unstructured":"Legato MJ, Johnson PA, Manson JE. Consideration of sex differences in medicine to improve health care and patient outcomes. JAMA. 2016;316(18):1865\u20136. \n                    https:\/\/doi.org\/10.1001\/jama.2016.13995\n                    \n                  .","journal-title":"JAMA."},{"key":"690_CR20","unstructured":"Ontario Ministry of Finance. Ontario population projections update, 2017\u20132041. \n                    https:\/\/www.fin.gov.on.ca\/en\/economy\/demographics\/projections\n                    \n                  . Accessed 1 Oct 2018."},{"issue":"1","key":"690_CR21","doi-asserted-by":"publisher","first-page":"337","DOI":"10.3233\/JAD-160105","volume":"54","author":"RL Jaakkimainen","year":"2016","unstructured":"Jaakkimainen RL, Bronskill SE, Tierney MC, Herrmann N, Green D, Young J, et al. Identification of physician-diagnosed Alzheimer\u2019s disease and related dementias in population-based administrative data: a validation study using family physicians\u2019 electronic medical records. J Alzheimers Dis. 2016;54(1):337\u201349. \n                    https:\/\/doi.org\/10.3233\/JAD-160105\n                    \n                  .","journal-title":"J Alzheimers Dis."},{"key":"690_CR22","unstructured":"Alzheimer\u2019s Society UK. Drug treatments for Alzheimer\u2019s disease. \n                    https:\/\/www.alzheimers.org.uk\/info\/20162\/drugs\/105\/drug_treatments_for_alzheimers_disease\/7\n                    \n                  . Accessed 19 Jun 2017."},{"key":"690_CR23","unstructured":"The National Institute on Aging\u2019s Alzheimer\u2019s Disease Education and Referral (ADEAR) Center. Alzheimer\u2019s disease medications. \n                    https:\/\/www.nia.nih.gov\/sites\/default\/files\/alzheimers-disease-medications-fact-sheet_1.pdf\n                    \n                  . Accessed 21 Jul 2017."},{"key":"690_CR24","doi-asserted-by":"publisher","first-page":"e1086","DOI":"10.1136\/bmj.e1086","volume":"344","author":"LM Schwartz","year":"2012","unstructured":"Schwartz LM, Woloshin S. How the FDA forgot the evidence: the case of donepezil 23 mg. BMJ. 2012;344:e1086. \n                    https:\/\/doi.org\/10.1136\/bmj.e1086\n                    \n                  .","journal-title":"BMJ."},{"issue":"10","key":"690_CR25","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1503\/cmaj.081103","volume":"179","author":"DB Hogan","year":"2008","unstructured":"Hogan DB, Bailey P, Black S, Carswell A, Chertkow H, Clarke B, et al. Diagnosis and treatment of dementia: 5. Nonpharmacologic and pharmacologic therapy for mild to moderate dementia. CMAJ. 2008;179(10):1019\u201326. \n                    https:\/\/doi.org\/10.1503\/cmaj.081103\n                    \n                  .","journal-title":"CMAJ."},{"issue":"5","key":"690_CR26","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1001\/archinternmed.2007.106","volume":"168","author":"JL Rudolph","year":"2008","unstructured":"Rudolph JL, Salow MJ, Angelini MC, McGlinchey RE. The anticholinergic risk scale and anticholinergic adverse effects in older persons. Arch Intern Med. 2008;168(5):508\u201313. \n                    https:\/\/doi.org\/10.1001\/archinternmed.2007.106\n                    \n                  .","journal-title":"Arch Intern Med."},{"key":"690_CR27","unstructured":"Ontario Ministry of Health and Long-Term Care. New eligibility requirements for the low-income Seniors Co-Payment Drug Program. \n                    http:\/\/www.health.gov.on.ca\/en\/public\/programs\/drugs\/programs\/copayment\/copayment.aspx\n                    \n                  . Accessed 30 Jun 2019."},{"key":"690_CR28","unstructured":"Johns Hopkins University. Johns Hopkins ACG case-mix adjustment system. \n                    https:\/\/www.hopkinsacg.org\n                    \n                  . Modified 2018. Accessed 17 Sep 2017."},{"issue":"1","key":"690_CR29","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1186\/s12877-017-0621-2","volume":"17","author":"N Masnoon","year":"2017","unstructured":"Masnoon N, Shakib S, Kalisch-Ellett L, Caughey GE. What is polypharmacy? A systematic review of definitions. BMC Geriatr. 2017;17(1):230. \n                    https:\/\/doi.org\/10.1186\/s12877-017-0621-2\n                    \n                  .","journal-title":"BMC Geriatr."},{"issue":"6","key":"690_CR30","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1080\/03610910902859574","volume":"38","author":"PC Austin","year":"2009","unstructured":"Austin PC. Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research. Commun Stat Simul Comput. 2009;38(6):1228\u201334.","journal-title":"Commun Stat Simul Comput."},{"issue":"1","key":"690_CR31","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.jclinepi.2008.11.004","volume":"63","author":"PC Austin","year":"2010","unstructured":"Austin PC. Absolute risk reductions, relative risks, relative risk reductions, and numbers needed to treat can be obtained from a logistic regression model. J Clin Epidemiol. 2010;63(1):2\u20136. \n                    https:\/\/doi.org\/10.1016\/j.jclinepi.2008.11.004\n                    \n                  .","journal-title":"J Clin Epidemiol."},{"issue":"7","key":"690_CR32","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1002\/pds.1613","volume":"17","author":"A Pariente","year":"2008","unstructured":"Pariente A, Helmer C, Merliere Y, Moore N, Fourrier-Reglat A, Dartigues JF. Prevalence of cholinesterase inhibitors in subjects with dementia in Europe. Pharmacoepidemiol Drug Saf. 2008;17(7):655\u201360. \n                    https:\/\/doi.org\/10.1002\/pds.1613\n                    \n                  .","journal-title":"Pharmacoepidemiol Drug Saf."},{"issue":"5","key":"690_CR33","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1111\/jgs.12210","volume":"61","author":"GB Rattinger","year":"2013","unstructured":"Rattinger GB, Burcu M, Dutcher SK, Chhabra PT, Rosenberg PB, Simoni-Wastila L, et al. Pharmacotherapeutic management of dementia across settings of care. J Am Geriatr Soc. 2013;61(5):723\u201333. \n                    https:\/\/doi.org\/10.1111\/jgs.12210\n                    \n                  .","journal-title":"J Am Geriatr Soc."},{"issue":"10","key":"690_CR34","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1111\/j.1532-5415.2007.01377.x","volume":"55","author":"N Herrmann","year":"2007","unstructured":"Herrmann N, Gill SS, Bell CM, Anderson GM, Bronskill SE, Shulman KI, et al. A population-based study of cholinesterase inhibitor use for dementia. J Am Geriatr Soc. 2007;55(10):1517\u201323. \n                    https:\/\/doi.org\/10.1111\/j.1532-5415.2007.01377.x\n                    \n                  .","journal-title":"J Am Geriatr Soc."},{"key":"690_CR35","unstructured":"Pfizer. Product monograph: Aricept (donepezil hydrochloride) tablets 5 and 10 mg. \n                    https:\/\/www.pfizer.ca\/sites\/g\/files\/g10037206\/f\/201612\/ARICEPT_PM_E_177353_18Dec2014_R.pdf\n                    \n                  . Revised December 18, 2014. Accessed 15 Jul 2018."},{"issue":"11","key":"690_CR36","doi-asserted-by":"publisher","first-page":"775","DOI":"10.7326\/0003-4819-146-11-200706050-00006","volume":"146","author":"SS Gill","year":"2007","unstructured":"Gill SS, Bronskill SE, Normand SL, Anderson GM, Sykora K, Lam K, et al. Antipsychotic drug use and mortality in older adults with dementia. Ann Intern Med. 2007;146(11):775\u201386.","journal-title":"Ann Intern Med."},{"key":"690_CR37","doi-asserted-by":"publisher","first-page":"a1227","DOI":"10.1136\/bmj.a1227","volume":"337","author":"IJ Douglas","year":"2008","unstructured":"Douglas IJ, Smeeth L. Exposure to antipsychotics and risk of stroke: self controlled case series study. BMJ. 2008;337:a1227. \n                    https:\/\/doi.org\/10.1136\/bmj.a1227\n                    \n                  .","journal-title":"BMJ."},{"key":"690_CR38","doi-asserted-by":"publisher","first-page":"h369","DOI":"10.1136\/bmj.h369","volume":"350","author":"HC Kales","year":"2015","unstructured":"Kales HC, Gitlin LN, Lyketsos CG. Assessment and management of behavioral and psychological symptoms of dementia. BMJ. 2015;350:h369. \n                    https:\/\/doi.org\/10.1136\/bmj.h369\n                    \n                  .","journal-title":"BMJ."},{"issue":"8","key":"690_CR39","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1503\/cmaj.070803","volume":"179","author":"DB Hogan","year":"2008","unstructured":"Hogan DB, Bailey P, Black S, Carswell A, Chertkow H, Clarke B, et al. Diagnosis and treatment of dementia: 4. Approach to management of mild to moderate dementia. CMAJ. 2008;179(8):787\u201393. \n                    https:\/\/doi.org\/10.1503\/cmaj.070803\n                    \n                  .","journal-title":"CMAJ."},{"issue":"3","key":"690_CR40","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s40266-014-0154-8","volume":"31","author":"SM Fereshtehnejad","year":"2014","unstructured":"Fereshtehnejad SM, Johnell K, Eriksdotter M. Anti-dementia drugs and co-medication among patients with Alzheimer\u2019s disease : investigating real-world drug use in clinical practice using the Swedish Dementia Quality Registry (SveDem). Drugs Aging. 2014;31(3):215\u201324. \n                    https:\/\/doi.org\/10.1007\/s40266-014-0154-8\n                    \n                  .","journal-title":"Drugs Aging."},{"issue":"4","key":"690_CR41","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1093\/ageing\/afw074","volume":"45","author":"SG Morgan","year":"2016","unstructured":"Morgan SG, Weymann D, Pratt B, Smolina K, Gladstone EJ, Raymond C, et al. Sex differences in the risk of receiving potentially inappropriate prescriptions among older adults. Age Ageing. 2016;45(4):535\u201342. \n                    https:\/\/doi.org\/10.1093\/ageing\/afw074\n                    \n                  .","journal-title":"Age Ageing."}],"container-title":["Drugs & Aging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-019-00690-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40266-019-00690-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-019-00690-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,13]],"date-time":"2020-07-13T23:12:45Z","timestamp":1594681965000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40266-019-00690-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,15]]},"references-count":41,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["690"],"URL":"https:\/\/doi.org\/10.1007\/s40266-019-00690-9","relation":{},"ISSN":["1170-229X","1179-1969"],"issn-type":[{"value":"1170-229X","type":"print"},{"value":"1179-1969","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,15]]},"assertion":[{"value":"15 July 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This study was supported by a grant from Physicians Services Incorporated (PSI 2015-16).The opinions, results, and conclusions reported in this paper are those of the authors and are independent from the funding sources. This study also was supported by ICES, which is funded by an annual grant from the Ontario Ministry of Health and Long-Term Care. Paula A. Rochon is supported by the Retired Teachers of Ontario\/ERO Chair in Geriatric Medicine at the University of Toronto. Peter C. Austin was supported by a Mid-Career Investigator Award from the Heart and Stroke Foundation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Lynn Zhu, Paula A. Rochon, Andrea Gruneir, Wei Wu, Vasily Giannakeas, Peter C. Austin, Nathan M. Stall, Lisa McCarthy, Amanda Alberga, Nathan Herrmann, Sudeep S. Gill, and Susan E. Bronskill have no conflicts of interest that are directly relevant to the contents of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"ICES is a prescribed entity under section\u00a045 of Ontario\u2019s Personal Health Information Protection Act. Section\u00a045 authorizes ICES to collect personal health information, without consent, for the purpose of analysis or compiling statistical information with respect to the management of, evaluation or monitoring of, the allocation of resources to or planning for all or part of the health system. Projects conducted under section\u00a045, by definition, do not require review by a research ethics board. This project was conducted under section\u00a045, and approved by the ICES\u2019 Privacy and Legal Office.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}}]}}